HC SURGICAL SPECIALISTSLIMITED (1B1) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of HC SURGICAL SPECIALISTSLIMITED S$0.71, price S$0.36, upside +97.2%, quality 83 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch HC SURGICAL SPECIALISTSLIMITED for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
HC Surgical Specialists Limited, an investment holding company, provides medical services primarily in Singapore. The company provides endoscopic procedures, including gastroscopies and colonoscopies; and general surgery services with a focus on colorectal procedures in a network of clinics.
Show more
HC Surgical Specialists Limited, an investment holding company, provides medical services primarily in Singapore. The company provides endoscopic procedures, including gastroscopies and colonoscopies; and general surgery services with a focus on colorectal procedures in a network of clinics. It also offers treatment services for other conditions, such as haemorrhoids, anal fissure, hernia, anal abscess, cholecystitis, anal fistula, appendicitis, colorectal cancer, lipomas, cysts, and gastric cancer, vein laser vascular, laparoscopy, and other general and specialized medical services. In addition, the company provides orthopedic services comprising joint pain, sports injuries, osteoarthritis, rotator cuff tears, trigger finger, wounds/lumps, tenosynovitis, tunnel syndrome, bumps, joint replacement, arthroscopic surgery, knee osteotomy, realignment surgery, endoscopic spine surgery, disc replacements, spinal decompression, fractures, and orthobiologic injections. Further, it provides home care services, which include medical, nursing, physiotherapy, speech therapy, occupational therapy, and ambulance services; health screening, management of acute and chronic conditions, and pre-employment check-up; public health preparedness clinic scheme, swab and send home program, community health assist scheme, and COVID-19 swab test services. Additionally, the company offers diagnostic tests that comprise blood tests, X-Rays, ultrasound, CT scans, and MRIs. HC Surgical Specialists Limited was incorporated in 2015 and is based in Singapore.
Stock analysis
HC SURGICAL SPECIALISTSLIMITED (1B1) currently trades at 0.3600 SGD, while our model-based Fair Value estimate is 0.7100 SGD, implying the stock looks roughly 49.3% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 0.9900 SGD per share, and 19 of the 24 models we run sit above the 0.3600 SGD price.
Bear case: the Asset-Based group reads lowest at 0.0900 SGD, and 5 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.5000 SGD (bear) to 0.9000 SGD (bull), the price of 0.3600 SGD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 83/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
HC SURGICAL SPECIALISTSLIMITED reported revenue of 19.1M SGD in FY2025 versus 23.4M SGD in FY2021, a compound −4.9%/yr. Reported net income was 8.4M SGD in FY2025, compounding +1.3%/yr from FY2021.
Key figures
Market cap 55.2M SGD (≈ $43.2M) · P/E ratio 7.2 · P/S ratio 3.18 · EPS (TTM) 0.0500 SGD · Dividend yield 5.8% · Net margin 44.2% · Return on equity 34.8% · Return on assets (EBIT) 26.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at 97%, 1B1 screens cheaper than that median.
Fair Value models
Bear 0.5000 SGDFair Value 0.7100 SGDBull 0.9000 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (0.0290 SGD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.73/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Start year 2020 (pandemic). Over 10 years: +10.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +4.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.1%
Dividend (yield on the price)5.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.35% → 37%
⚠ Rate on operating basis: 2025 sits 120% above its own trend.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−9.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about −11.2% a year for the price.
Compare HC SURGICAL SPECIALISTSLIMITED with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 134 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score83 · Top 25%
Fair Value upside+97.2% · Top 25%
Profitability
Return on equity (TTM)34.8% · Top 25%
Return on assets10.4% · Top 25%
Net margin (TTM)35.3% · Top 25%
Operating margin (TTM)23.9% · Top 25%
Growth and dividend
Revenue growth−7.5% · Bottom 25%
Dividend yield (TTM)5.8% · Top 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is HC SURGICAL SPECIALISTSLIMITED (1B1) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 0.7100 SGD versus a price of 0.3600 SGD, about +97% upside (undervalued).
What is the fair value of 1B1?
Our model-based fair value for HC SURGICAL SPECIALISTSLIMITED is 0.7100 SGD (as of Oct 3, 2026), built from audited fundamentals. The current price: 0.3600 SGD.
What is the quality score of 1B1?
HC SURGICAL SPECIALISTSLIMITED has a Quality Score of 83/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HC SURGICAL SPECIALISTSLIMITED (1B1)?
Our model-based price target is the fair value of 0.7100 SGD (as of Oct 3, 2026) from 24 valuation models. Cautious scenario 0.5000 SGD, optimistic scenario 0.9000 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the HC SURGICAL SPECIALISTSLIMITED stock forecast for 2026?
Our models put fair value at 0.7100 SGD, about +97% upside versus a price of 0.3600 SGD (undervalued). Cautious scenario 0.5000 SGD, optimistic scenario 0.9000 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of HC SURGICAL SPECIALISTSLIMITED (1B1)?
HC SURGICAL SPECIALISTSLIMITED reported trailing-twelve-month revenue of about 19.8M SGD (latest available figure, as of Oct 3, 2026).
Does HC SURGICAL SPECIALISTSLIMITED pay a dividend?
HC SURGICAL SPECIALISTSLIMITED currently shows a dividend yield of about 5.83% relative to its recent price (as of Oct 3, 2026).
What growth is priced into HC SURGICAL SPECIALISTSLIMITED (1B1)?
For today's price to be fair in a discounted-cash-flow model, HC SURGICAL SPECIALISTSLIMITED would have to grow free cash flow by -9.4 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.7 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of 1B1 use?
Our models discount HC SURGICAL SPECIALISTSLIMITED at 9.5 %: a base by market capitalisation (nano), country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For HC SURGICAL SPECIALISTSLIMITED that is -9.4 % per year a year over ten years, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has HC SURGICAL SPECIALISTSLIMITED (1B1) delivered so far?
Over the past 5 years revenue at HC SURGICAL SPECIALISTSLIMITED grew +2.7 % a year. The price currently implies -9.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of HC SURGICAL SPECIALISTSLIMITED (1B1) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into HC SURGICAL SPECIALISTSLIMITED (-9.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The free-cash-flow yield on the price is 12.22 %: that much free cash flow HC SURGICAL SPECIALISTSLIMITED produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of HC SURGICAL SPECIALISTSLIMITED (1B1)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HC SURGICAL SPECIALISTSLIMITED it is 0.7100 SGD per share (as of Oct 3, 2026), against a price of 0.3600 SGD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is HC SURGICAL SPECIALISTSLIMITED stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 1B1 trades below its calculated fair value: price 0.3600 SGD, fair value 0.7100 SGD, a gap of about +97% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1B1?
No. The price is what the market pays today (0.3600 SGD); the fair value is what the company's own numbers justify (0.7100 SGD). For HC SURGICAL SPECIALISTSLIMITED the two are 0.3500 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is HC SURGICAL SPECIALISTSLIMITED worth?
The market values HC SURGICAL SPECIALISTSLIMITED at about 55.2M SGD (market capitalisation, as of Oct 3, 2026). Per share that is 0.3600 SGD; our models calculate a fair value of 0.7100 SGD per share.
What do the bullish and bearish scenarios say about 1B1?
Our models span a range for HC SURGICAL SPECIALISTSLIMITED: cautious scenario 0.5000 SGD, base 0.7100 SGD, optimistic 0.9000 SGD per share (as of Oct 3, 2026, price 0.3600 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1B1?
HC SURGICAL SPECIALISTSLIMITED trades at a price-to-earnings ratio of 7.2 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.7100 SGD is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2025), reported earnings: 11.6. Other multiples: P/B 2.6, P/S 2.8, EV/EBITDA 9.3.
How solid is the balance sheet of HC SURGICAL SPECIALISTSLIMITED (1B1)?
Balance-sheet figures for HC SURGICAL SPECIALISTSLIMITED (as of Oct 3, 2026): return on equity 34.8%. They feed the Quality Score of 83/100, which measures business quality independently of the share price.
How far is 1B1 from its 52-week high?
HC SURGICAL SPECIALISTSLIMITED trades at 0.3600 SGD, about 10% below its 52-week high of 0.4000 SGD and 11% above the low of 0.3251 SGD (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 0.7100 SGD is for.
Which stocks are comparable to HC SURGICAL SPECIALISTSLIMITED?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HC SURGICAL SPECIALISTSLIMITED stock attractive at the current price?
The data as of Oct 3, 2026: price 0.3600 SGD, calculated fair value 0.7100 SGD (+97%), Quality Score 83/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1B1 calculated?
We run HC SURGICAL SPECIALISTSLIMITED through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.7100 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. HC SURGICAL SPECIALISTSLIMITED currently trades 49 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The closing price on Oct 2, 2026 was 0.3600 SGD. Our model-based fair value is 0.7100 SGD, about +97% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HC SURGICAL SPECIALISTSLIMITED right now?
The rarer combination: high quality (83/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (0.5000 SGD). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (0.5000 SGD to 0.9000 SGD) leaves room in how you read the outcome.
Key figures of HC SURGICAL SPECIALISTSLIMITED
How large is the market capitalisation of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The market capitalisation of HC SURGICAL SPECIALISTSLIMITED is 55.2M SGD (≈ $43.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The price-to-sales ratio of HC SURGICAL SPECIALISTSLIMITED is 3.18 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HC SURGICAL SPECIALISTSLIMITED (1B1)?
Earnings per share at HC SURGICAL SPECIALISTSLIMITED are 0.0500 SGD (price ÷ EPS = P/E 7.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The dividend yield of HC SURGICAL SPECIALISTSLIMITED is 5.8% (payout 42.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The net margin of HC SURGICAL SPECIALISTSLIMITED is 44.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The return on equity (ROE) of HC SURGICAL SPECIALISTSLIMITED is 34.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HC SURGICAL SPECIALISTSLIMITED (1B1)?
On an EBIT basis the return on assets of HC SURGICAL SPECIALISTSLIMITED is 26.2% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HC SURGICAL SPECIALISTSLIMITED (1B1)?
The operating margin of HC SURGICAL SPECIALISTSLIMITED is 23.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HC SURGICAL SPECIALISTSLIMITED (1B1)?
Revenue at HC SURGICAL SPECIALISTSLIMITED is growing −7.5% versus a year earlier (3y avg −0.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HC SURGICAL SPECIALISTSLIMITED (1B1)?
Earnings per share at HC SURGICAL SPECIALISTSLIMITED are growing −40.3% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch HC SURGICAL SPECIALISTSLIMITED in the live analysis
One click puts HC SURGICAL SPECIALISTSLIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
